509 related articles for article (PubMed ID: 25453735)
21. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Ogasa M; Kimura T; Nakamura M; Guarino J
Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
[TBL] [Abstract][Full Text] [Related]
22. Lurasidone: a clinical overview.
Kane JM
J Clin Psychiatry; 2011; 72 Suppl 1():24-8. PubMed ID: 22217440
[TBL] [Abstract][Full Text] [Related]
23. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
24. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
[TBL] [Abstract][Full Text] [Related]
26. Lurasidone : in the treatment of schizophrenia.
Sanford M
CNS Drugs; 2013 Jan; 27(1):67-80. PubMed ID: 23264146
[TBL] [Abstract][Full Text] [Related]
27. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
[TBL] [Abstract][Full Text] [Related]
28. Lurasidone for schizophrenia: what's different?
Kantrowitz JT; Citrome L
Expert Rev Neurother; 2012 Mar; 12(3):265-73. PubMed ID: 22364325
[TBL] [Abstract][Full Text] [Related]
29. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Citrome L
Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
[TBL] [Abstract][Full Text] [Related]
31. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A; Cucchiaro J; Silva R; Kroger H; Hsu J; Sarma K; Sachs G
Am J Psychiatry; 2014 Feb; 171(2):160-8. PubMed ID: 24170180
[TBL] [Abstract][Full Text] [Related]
32. A review of published evidence reporting on the efficacy and pharmacology of lurasidone.
McIntyre RS; Cha DS; Alsuwaidan M; McIntosh D; Powell AM; Jerrell JM
Expert Opin Pharmacother; 2012 Aug; 13(11):1653-9. PubMed ID: 22559286
[TBL] [Abstract][Full Text] [Related]
33. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
34. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
[TBL] [Abstract][Full Text] [Related]
35. Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Yasui-Furukori N
Drug Des Devel Ther; 2012; 6():107-15. PubMed ID: 22675261
[TBL] [Abstract][Full Text] [Related]
36. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
[TBL] [Abstract][Full Text] [Related]
37. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
38. [Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - lurasidone].
Bieńkowski P; Dudek D; Samochowiec J
Psychiatr Pol; 2015; 49(2):243-53. PubMed ID: 26093589
[TBL] [Abstract][Full Text] [Related]
39. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
Nasrallah HA; Cucchiaro JB; Mao Y; Pikalov AA; Loebel AD
CNS Spectr; 2015 Apr; 20(2):140-7. PubMed ID: 24955752
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
